The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 636,458 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 5.47% since March 24, 2016 and is downtrending. It has underperformed by 8.94% the S&P500.
The move comes after 7 months negative chart setup for the $1.76 billion company. It was reported on Oct, 31 by Barchart.com. We have $2.61 PT which if reached, will make TSE:PLI worth $158.40M less.
ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage
Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ProMetic Life Sciences Inc. has been the topic of 18 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by RBC Capital Markets on Thursday, October 27. The rating was reinitiated by Paradigm Research with “Buy” on Monday, September 28. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by Scotia Capital on Thursday, August 11. The company was maintained on Tuesday, December 8 by RBC Capital Markets. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, October 5 report. As per Wednesday, June 15, the company rating was maintained by RBC Capital Markets. As per Monday, August 10, the company rating was maintained by Scotia Capital. TD Securities maintained the shares of PLI in a report on Thursday, October 27 with “Speculative Buy” rating. RBC Capital Markets maintained ProMetic Life Sciences Inc. (TSE:PLI) on Thursday, August 25 with “Outperform” rating. Scotia Capital maintained it with “Outperform” rating and $5 target price in Thursday, October 27 report.
More important recent ProMetic Life Sciences Inc. (TSE:PLI) news were published by: Prnewswire.com which released: “Telesta Therapeutics Inc. announces closing of arrangement with Prometic Life …” on October 31, 2016, also Fool.ca published article titled: “What Is Inflaming ProMetic Life Sciences Inc.’s Latest Increase?”, Prnewswire.com published: “Telesta Therapeutics Inc. announces final court approval of plan of …” on October 28, 2016. More interesting news about ProMetic Life Sciences Inc. (TSE:PLI) was released by: Marketwatch.com and their article: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” with publication date: March 11, 2016.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.76 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.